Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients.
CTLA-4
PD-1
PD-L1
acute vascular events
arterial thrombosis
atherosclerosis
ischemic stroke
myocardial infarction
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
01
2021
accepted:
27
04
2021
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
15
6
2021
Statut:
epublish
Résumé
In clinical trials and meta-analysis, atherosclerotic vascular events (AVEs) during treatment with immune-checkpoint inhibitors (ICIs) have been reported with low incidence. However, preclinical data suggest that these drugs can promote atherosclerosis inflammation and progression of atherosclerosis plaques, and there is now growing and convincing evidence from retrospective studies that ICIs increase the risk of atherosclerotic vascular events including arterial thrombosis, myocardial infarction and ischemic stroke. Prospective studies are needed to increase knowledge on long-term effect of ICIs or their combinations with other cardio-toxic drugs, but in the meantime a careful assessment and optimization of cardiovascular risk factors among patients treated with ICIs is advisable.
Identifiants
pubmed: 34124192
doi: 10.3389/fcvm.2021.652186
pmc: PMC8193098
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
652186Informations de copyright
Copyright © 2021 Inno, Chiampan, Lanzoni, Verzè, Molon and Gori.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Cardiol. 2019 Jun;16(6):325-343
pubmed: 30770894
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Cells. 2020 Aug 29;9(9):
pubmed: 32872393
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Nat Rev Nephrol. 2017 Jun;13(6):368-380
pubmed: 28392564
Clin Chim Acta. 2020 Jun;505:26-30
pubmed: 32084380
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1100-7
pubmed: 21393583
Eur J Cancer. 2018 Mar;91:164-166
pubmed: 29289455
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
PLoS One. 2014 Apr 01;9(4):e93280
pubmed: 24691202
Lancet. 2018 Mar 10;391(10124):933
pubmed: 29536852
Ann Oncol. 2018 Jan 1;29(1):284-286
pubmed: 29106493
Target Oncol. 2018 Aug;13(4):509-515
pubmed: 30006825
World J Cardiol. 2020 Nov 26;12(11):584-598
pubmed: 33312443
Cardiovasc Pathol. 2019 Nov - Dec;43:107148
pubmed: 31518915
Cancers (Basel). 2019 Dec 25;12(1):
pubmed: 31881699
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Mediators Inflamm. 2015;2015:364710
pubmed: 25684861
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Lancet Oncol. 2018 Sep;19(9):e447-e458
pubmed: 30191849
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32034065
Curr Oncol Rep. 2020 Jun 8;22(7):65
pubmed: 32514647
Arch Med Sci Atheroscler Dis. 2017 Dec 31;2:e100-e102
pubmed: 29379889
Am J Med Sci. 2019 Apr;357(4):343-347
pubmed: 30638772
J Clin Invest. 2007 Oct;117(10):2974-82
pubmed: 17853943
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Thromb Res. 2020 Dec;196:444-453
pubmed: 33065409
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Ann Oncol. 2017 Nov 1;28(11):2893-2895
pubmed: 28651328
Circulation. 2020 Dec 15;142(24):2299-2311
pubmed: 33003973
Nat Immunol. 2011 Mar;12(3):204-12
pubmed: 21321594
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S8-S20
pubmed: 29299404
Eur J Cancer. 2019 Oct;120:122-131
pubmed: 31518968
Ther Adv Med Oncol. 2020 Jul 24;12:1758835920913801
pubmed: 32782484
N Engl J Med. 2012 Jun 28;366(26):2517-9
pubmed: 22658126
Tumori. 2017 Sep 18;103(5):405-421
pubmed: 28497847